


# Varvel Lab 2020-2022 Highlights



## Peripheral immune Cells as a Target in Brain Disease

### Active Grants

Principle Investigator	Start Date	Funding Org	Current Yr Funding	Duration
Varvel	12/2019	R01 NINDS	\$341,250	5 years
Varvel	7/2019	BrightFocus Foundation	\$100,000	4 years
Dingledine/Varvel	6/2020	R01 NINDS	\$520,230	5 years



Alzheimer's disease pathology  
and microglia recruitment



### Publications

**Varvel NH**, Espinosa-Garcia C, Hunter-Chang S, Chen D, Biegel A, Hsieh A, Blackmer-Raynolds L, Ganesh T, Dingledine R. (2021) Peripheral myeloid cell EP2 activation contributes to the deleterious consequences of status epilepticus. *Journal of Neuroscience*. **41**, 1105-1117

Manji Z, Rojas A, Wang W, Dingledine R, **Varvel NH**, Ganesh T. (2019) 5xFAD mice display sex-dependent inflammatory gene induction during the prodromal stage of Alzheimer's disease. *Journal of Alzheimer's Disease* **70**, 1259-1274

Dingledine R, Ravizza T, **Varvel NH**, Vezzani A. Neuroinflammation in epilepsy: cellular and molecular mechanisms. *Jasper's Basic Mechanisms of the Epilepsies*.

Vezzani A, Balosso S, **Varvel NH**, Dingledine R. Anti-inflammatory strategies for disease modification: focus on therapies close to clinical translation. *Jasper's Basic Mechanisms of the Epilepsies*.